Nyrada Inc. (ASX:NYR)
Australia · Delayed Price · Currency is AUD 0.7200
+0.0350 (5.11%)
Sep 10, 2026, 4:10 PM AEST
Nyrada Revenue
In the fiscal year ending June 30, 2026, Nyrada had annual revenue of 2.01M AUD, down -16.08%. Nyrada had revenue of 1.23M in the half year ending June 30, 2026, with 44.66% growth.
Revenue
2.01M
Revenue Growth
-16.08%
P/S Ratio
88.45
Revenue / Employee
n/a
Employees
n/a
Market Cap
177.91M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 2.01M | -385.39K | -16.08% |
| Jun 30, 2025 | 2.40M | -845.19K | -26.07% |
| Jun 30, 2024 | 3.24M | 1.81M | 126.72% |
| Jun 30, 2023 | 1.43M | 336.16K | 30.73% |
| Jun 30, 2022 | 1.09M | -1.24M | -53.18% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BLS Pharmaceuticals | 73.91M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
| Orthocell | 11.41M |
| Recce Pharmaceuticals | 9.47M |
| Dimerix | 6.35M |
| Tetratherix | 3.86M |
| Alterity Therapeutics | 3.61M |